A Booming Bioscience Scene

A Nucleus of Innovation

More than 17,000 bioscience workers are employed across more than 500 companies in Connecticut¹. Together they form a collaborative ecosystem advancing bioscience innovation – fueled by the strong public/private R&D partnerships across Connecticut’s universities, bioscience companies, venture capital investors and state government.

Contribute to the Practical Application of Theoretical Advances

Thanks to the close working relationships of Connecticut’s world-class universities, businesses and healthcare systems, Connecticut bioscience companies excel at making the possible practical.

At The Jackson Laboratory for Genomic Medicine in Farmington, scientists are discovering the genomic causes of human disease to develop individualized diagnostics, treatments and cures. At leading research and development centers for pharmaceutical giants Pfizer and Boehringer Ingelheim, researchers are developing new drugs across a wide array of therapeutic areas. And at hundreds of emerging bioscience companies all across Connecticut, entrepreneurs are making huge contributions to the field — developing alternative low-toxic treatments for cancers, leveraging artificial intelligence to dramatically shorten the time it takes to bring a drug to market, employing bioinformatics to analyze complex genetic codes and much more.

Become Part of a Community of Bioscience Innovators

One reason Connecticut is such a center for innovation in the field is that it has one of America’s highest concentrations of scientists and engineers — many of whom work in the state’s bioscience sector.

Fostering their innovations is a commitment shared by Connecticut’s universities, the state government, and leading companies. For example:

Pfizer has established the Pfizer Breakthrough Growth Initiative, which has pledged to invest up to $500 million in promising biotechnology companies.
Yale University professors run labs that give students an opportunity to apply what they’re learning to the development of new drugs and therapeutic strategies.
The state government established a $200 million Connecticut Bioscience Innovation Fund to speed the commercialization of bioscience breakthroughs.
The Connecticut state government also offers tax credits for angel investors, tax exemptions for the purchase of biotechnology equipment, R&D tax credits and a variety of other incentives to spur bioscience innovation.
The Accelerator for Biosciences in Connecticut (ABCT) offers a variety of programs to help the state’s most innovative startups develop a business plan, access mentorship, and pitch to potential investors.

Michael Marsland courtesy of Yale University

Innovation in action at The Jackson Laboratory

Standing strong at Pfizer

These are just a few examples of the type of support and the breadth of opportunities bioscience professionals will find in Connecticut — at the intersection of scientific innovation and market commercialization.

For more on Connecticut’s bioscience sector, be sure to also visit BioCT, an organization dedicated to connecting the state’s bioscience community by supporting its needs and serving as a leading voice of the industry.

¹Emsi, 2019; AdvanceCT calculations

A Few of Connecticut’s Bioscience Companies & Organizations

TEConomy/BIO, 2020

National Science Foundation, 2018; Bureau of Labor Statistics; 2017